Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "IP"

10216 News Found

Syngene announces 3rd year of STEM scholarship for women with RICH
News | July 11, 2025

Syngene announces 3rd year of STEM scholarship for women with RICH

This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background


Merck to present new research data across its HIV prevention and treatment pipeline at IAS 2025
Clinical Trials | July 09, 2025

Merck to present new research data across its HIV prevention and treatment pipeline at IAS 2025

Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment


European Commission fines Alchem for participating in API cartel
News | July 05, 2025

European Commission fines Alchem for participating in API cartel

The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle


Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy
News | July 03, 2025

Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy

ART-123 is a recombinant human thrombomodulin approved in Japan in 2008


Biocon concludes a Rs 4,500 crore equity fundraise through QIP
News | June 21, 2025

Biocon concludes a Rs 4,500 crore equity fundraise through QIP

The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures


Cipla Health launches a new campaign for Cipladine with Neena Gupta as brand ambassador
News | June 13, 2025

Cipla Health launches a new campaign for Cipladine with Neena Gupta as brand ambassador

Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films


Lubrizol's polymer excipient Apisolex featured in Phase I candidate
News | June 11, 2025

Lubrizol's polymer excipient Apisolex featured in Phase I candidate

The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold


iNGENu CRO, Quantum BioPharma to launch Australian trial for chronic nociplastic pain in MCAS patients
Clinical Trials | June 04, 2025

iNGENu CRO, Quantum BioPharma to launch Australian trial for chronic nociplastic pain in MCAS patients

The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure